Anzeige
Mehr »
Login
Dienstag, 07.02.2023 Börsentäglich über 12.000 News von 679 internationalen Medien
Noch einmal große Einstiegschance!? - Warum genau jetzt aktiv werden…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PS5P ISIN: US35104E1001 Ticker-Symbol:  
NASDAQ
06.02.23
22:00 Uhr
21,700 US-Dollar
0,000
0,00 %
1-Jahres-Chart
4D MOLECULAR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
4D MOLECULAR THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur 4D MOLECULAR THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrFDA places hold on 4D Molecular's Fabry gene therapy-
4D MOLECULAR THERAPEUTICS Aktie jetzt für 0€ handeln
Fr4D Molecular cleared to start mid-stage trial for diabetic macular edema candidate1
Fr4D Molecular Therapeutics, Inc. - 8-K, Current Report1
Do4D Molecular Therapeutics, Inc.: 4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema-
26.01.4D Molecular Therapeutics, Inc. - 8-K, Current Report1
10.01.4D Molecular pauses enrollment in Fabry trials after kidney problems in three patients2
09.01.4D Molecular Therapeutics, Inc.: 4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs-
15.12.22How Is The Market Feeling About 4D Molecular Therapeutics?1
18.11.22HC Wainwright Creates Bullish Pitch On 4D Molecular Citing 'Broader Systemic Potential'3
18.11.22Expert Ratings for 4D Molecular Therapeutics2
17.11.224D Molecular (FDMT) Stock Up 178% in One Month: Here's Why3
16.11.224D Molecular Therapeutics (FDMT) Stock Surges 38.55%: Details2
14.11.224D Molecular says its wet AMD therapy cuts Eylea burden2
14.11.224D Molecular Therapeutics Shares Jump After Early Data From Wet Age-Related Macular Degeneration Trial3
14.11.224D Molecular Therapeutics, Inc.: 4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)-
10.11.224D Molecular Therapeutics, Inc.: 4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be ...1
09.11.224D Molecular Therapeutics GAAP EPS of -$0.79 misses by $0.04, revenue of $0.5M misses by $3.17M-
09.11.224D Molecular Therapeutics, Inc. - 8-K, Current Report-
09.11.224D Molecular Therapeutics, Inc.: 4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results218- Interim clinical trial data from 4DMT's Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November...
► Artikel lesen
03.11.224D Molecular up 11% on early-stage data for cystic fibrosis lung disease candidate1
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1